Feasibility study of porcine dermal acellular matrix in artificial trachea replacement based on in-vivo bioreactor

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056696

Enrollment

Unknown

Registered

2022-02-10

Start date

2022-02-10

Completion date

Unknown

Last updated

2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tracheal tumor

Interventions

Artificial airway reconstruction:Porcine dermal acellular matrix

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with tracheal tumor or surrounding organ tumor involving the trachea, with a resection range of more than 6 cm, and unable to implement traditional end-to-end anastomosis; 2. Patients with lung cancer invading the first and second grade bronchus cannot undergo traditional bronchoplasty or sleeve resection, and need to undergo pneumonectomy. The replacement of bronchus with tissue engineered trachea substitutes can preserve the lung lobes.

Exclusion criteria

Exclusion criteria: 1. Patients with trachea defect less than 4 cm can be directly end-to-end anastomosis; 2. Patients with lung cancer invading the first and second grade bronchus can be cured by traditional bronchoplasty or sleeve resection, and the lung lobes can be preserved to avoid pneumonectomy; 3. Those who decide to withdraw from the test.

Design outcomes

Primary

Measure	Time frame
overall survival;	—

Countries

China

Contacts

Public ContactQiang Tan

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University (SJTU)

dr_tanqiang@sina.cn+86 13601860323

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026